SCHEDULE: BlackRock Discloses 8% Stake in SI-BONE, Inc.

BlackRock, Inc. has filed a Schedule 13G, reporting beneficial ownership of 8.0% of SI-BONE, Inc.'s common stock as of June 30, 2026.

Summary

• BlackRock, Inc. has filed an amendment to its Schedule 13G, indicating its beneficial ownership of SI-BONE, Inc. common stock.
• As of June 30, 2026, BlackRock beneficially owns 3,558,735 shares, representing 8.0% of the class of securities.
• This ownership includes sole voting power over 3,490,613 shares and sole dispositive power over 3,558,735 shares.
• The filing clarifies that BlackRock's ownership is held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. It's a routine disclosure of institutional ownership and does not provide new operational or financial information about SI-BONE, Inc. itself.

Positives

• BlackRock, a significant institutional investor, holds a substantial stake (8.0%) in SI-BONE, Inc., which can be viewed as a positive signal of confidence.
• The filing confirms that the securities are held in the ordinary course of business, suggesting a standard investment approach rather than a hostile takeover attempt.

Risks

• The filing does not contain specific risk factors related to SI-BONE, Inc. itself, as it is a disclosure of ownership by BlackRock.
• Potential future changes in BlackRock's investment strategy or market conditions could lead to a reduction in their stake, impacting SI-BONE's stock.

Future Outlook

The filing itself is a snapshot of current ownership and does not contain forward-looking statements or guidance from SI-BONE, Inc. regarding its future business operations or financial performance. BlackRock's future outlook for its investment in SI-BONE is not detailed.

Management Comments

• "BlackRock, Inc., a corporation duly organized under the laws of the State of Delaware, United States (the "Company"), does hereby make, constitute and appoint each of Eric Andruczyk, Richard Cundiff, R. Andrew Dickson, III, Spencer Fleming, Laura Hildner, David Maryles, Christopher Meade, Charles Park, James Raby, Daniel Riemer, David Rothenberg and Brenda Schulz, acting severally, as its true and lawful attorneys-in-fact..."
• "By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities..."

Industry Context

StockSavvy.ai notes that large institutional investors like BlackRock frequently file Schedule 13G disclosures to report significant ownership stakes. This filing indicates BlackRock's ongoing interest in SI-BONE, Inc., a company operating in the medical device sector, specifically in orthopedic implants.

Stakeholder Impact

• Shareholders: The filing confirms a significant institutional investor's stake, which may influence market perception and trading activity.
• Management of SI-BONE, Inc.: Awareness of BlackRock's substantial holding is important for strategic planning and investor relations.
• Potential Investors: The disclosure provides information about the ownership structure and the presence of a major fund manager.

Next Steps

• BlackRock will continue to monitor its investment in SI-BONE, Inc.
• SI-BONE, Inc. will continue its business operations as disclosed in its other filings.

Key Dates

Keywords

SI-BONE, BlackRock, Schedule 13G, Institutional Investor, Beneficial Ownership, Common Stock, Investment Holding